Monoclonal antibody Rituximab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection.

I Papakonstantinou, I Poulakidas

Open access · greenAbstract readCase Reports

In one paragraph

Article in Hippokratia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 42% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case Report.Medicine · 2015
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

I Papakonstantinou1 Department of Internal Medicine, 401 General Military Hospital of Athens, Greece401 General Military Hospital of Athens, Greece.

I PoulakidasHematology Division, 401 General Military Hospital of Athens, Greece401 General Military Hospital of Athens, Greece.

401 General Military Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere immune thrombocytopenia displays a rare side effect of pegylated interferon therapy for Hepatitis C infection. Our aim is to report a case of severe and late onset immune thrombocytopenia due to pegylated interferon treatment that was effectively managed with the anti-CD20 monoclonal antibody Rituximab. DESCRIPTION OF THE CASE: A 27-year-old male, Hepatitis C infected patient, presented with sudden, severe immune thrombocytopenia at the end of a standard 24-week antiviral treatment, as a side effect of pegylated interferon. Platelet count rapidly normalized with Rituximab infusions.

conclusionRituximab could be a valuable treatment option in pegylated interferon related immune thrombocytopenia, when patients are resistant to conventional treatment or when physicians are reluctant to administer corticosteroids.

Indexed as

HCVImmune thrombocytopeniapegylated interferonRituximab

Identifiers

PMID26052210

PMCPMC4453817

OpenAlexW2187847335

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.